Dekabank Deutsche Girozentrale Reduces $123K in Bicycle Therapeutics plc ($BCYC)
Key Points
- Dekabank Deutsche Girozentrale changed its Bicycle Therapeutics plc ($BCYC) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $BCYC is Buy and an average price target of $12.62.
- $BCYC last traded around $4.10.
Dekabank Deutsche Girozentrale reduced its position in Bicycle Therapeutics plc ($BCYC), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Bicycle Therapeutics plc after selling 30,000 shares during the quarter.
Bicycle Therapeutics plc ($BCYC) Stock
Bicycle Therapeutics plc Earnings
Analysts Set New Price Targets
About Bicycle Therapeutics plc
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.